EPISODE · Feb 7, 2025 · 9 MIN
Type 2 Diabetes Treatments and Major Adverse Cardiovascular Events by Age and Sex, Simvastatin with Rifaximin for Decompensated Liver Cirrhosis, Approved vs Off-label Doxepin Formulation Trends and more
Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from February 1-7, 2025.
Embed this episode
Ready to play
Type 2 Diabetes Treatments and Major Adverse Cardiovascular Events by Age and Sex, Simvastatin with Rifaximin for Decompensated Liver Cirrhosis, Approved vs Off-label Doxepin Formulation Trends and more
0:00
9:51
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of JAMA Editors' Summary?
This episode is 9 minutes long.
When was this JAMA Editors' Summary episode published?
This episode was published on February 7, 2025.
Can I download this JAMA Editors' Summary episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!